81 related articles for article (PubMed ID: 16721812)
1. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study.
Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; de Kok JB; Malmström PU
Int J Cancer; 2006 Oct; 119(8):1915-9. PubMed ID: 16721812
[TBL] [Abstract][Full Text] [Related]
2. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.
Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; Malmström PU; de Kok JB
Eur Urol; 2007 Feb; 51(2):416-22; discussion 422-3. PubMed ID: 16920253
[TBL] [Abstract][Full Text] [Related]
3. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
[TBL] [Abstract][Full Text] [Related]
4. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma.
Mengual L; Burset M; Ribal MJ; Ars E; Marín-Aguilera M; Fernández M; Ingelmo-Torres M; Villavicencio H; Alcaraz A
Clin Cancer Res; 2010 May; 16(9):2624-33. PubMed ID: 20406841
[TBL] [Abstract][Full Text] [Related]
5. Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results.
Mares J; Szakacsova M; Soukup V; Duskova J; Horinek A; Babjuk M
Neoplasma; 2013; 60(3):295-301. PubMed ID: 23452234
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence.
Schultz IJ; De Kok JB; Witjes JA; Babjuk M; Willems JL; Wester K; Swinkels DW; Tjalsma H
Anticancer Res; 2007; 27(2):1051-8. PubMed ID: 17465243
[TBL] [Abstract][Full Text] [Related]
7. Identifying distinct classes of bladder carcinoma using microarrays.
Dyrskjøt L; Thykjaer T; Kruhøffer M; Jensen JL; Marcussen N; Hamilton-Dutoit S; Wolf H; Orntoft TF
Nat Genet; 2003 Jan; 33(1):90-6. PubMed ID: 12469123
[TBL] [Abstract][Full Text] [Related]
8. Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
Denzinger S; Stoehr R; Schwarz S; Eichenseher N; Brockhoff G; Obermann EC; Knuechel R; Blaszyk H; Hartmann A; Wild PJ
Int J Oncol; 2007 Oct; 31(4):793-802. PubMed ID: 17786310
[TBL] [Abstract][Full Text] [Related]
9. Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.
Mangrud OM; Gudlaugsson E; Skaland I; Tasdemir I; Dalen I; van Diermen B; Baak JP; Janssen EA
Hum Pathol; 2014 Jul; 45(7):1496-503. PubMed ID: 24796506
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
12. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays.
Wang Y; Barbacioru C; Hyland F; Xiao W; Hunkapiller KL; Blake J; Chan F; Gonzalez C; Zhang L; Samaha RR
BMC Genomics; 2006 Mar; 7():59. PubMed ID: 16551369
[TBL] [Abstract][Full Text] [Related]
13. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer.
Bartoletti R; Cai T; Nesi G; Roberta Girardi L; Baroni G; Dal Canto M
J Surg Res; 2007 Dec; 143(2):422-7. PubMed ID: 17612565
[TBL] [Abstract][Full Text] [Related]
14. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
15. Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.
Avgeris M; Mavridis K; Tokas T; Stravodimos K; Fragoulis EG; Scorilas A
Carcinogenesis; 2015 May; 36(5):528-37. PubMed ID: 25804644
[TBL] [Abstract][Full Text] [Related]
16. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers.
Kim YJ; Ha YS; Kim SK; Yoon HY; Lym MS; Kim MJ; Moon SK; Choi YH; Kim WJ
Clin Cancer Res; 2010 Apr; 16(7):2131-7. PubMed ID: 20233890
[TBL] [Abstract][Full Text] [Related]
17. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
Schultz IJ; Kiemeney LA; Witjes JA; Schalken JA; Willems JL; Swinkels DW; de Kok JB
Anticancer Res; 2003; 23(4):3327-31. PubMed ID: 12926071
[TBL] [Abstract][Full Text] [Related]
18. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
Liu B; Miyake H; Nishikawa M; Fujisawa M
Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
[TBL] [Abstract][Full Text] [Related]
19. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
